( NASDAQ-NMS:ITMN )

News from intermune, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Sep 29, 2014, 01:01 ET Roche purchases shares in tender offer for InterMune, Inc.

Roche (SIX: RO, ROG; OTCQX: RHHBY) and InterMune, Inc. (NASDAQ: ITMN) today announced that Roche's wholly owned subsidiary Klee...


Sep 19, 2014, 21:51 ET InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action

 InterMune, Inc. (Nasdaq: ITMN) today announced that it entered into a Memorandum of Understanding to settle the litigation in the Delaware...


Sep 05, 2014, 08:00 ET InterMune Announces Anticipated Fundamental Change for 5.00% Convertible Senior Notes Due 2015

 InterMune, Inc. (Nasdaq: ITMN) today provided the following notice to the indenture trustee and holders of its outstanding 5.00% Convertible...


Aug 06, 2014, 16:01 ET InterMune Reports Second Quarter 2014 Financial Results and Business Highlights

 InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the second quarter ended June 30, 2014.  The company also...


Jul 28, 2014, 08:00 ET InterMune to Release Second Quarter Financial Results on August 6

 InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its second quarter 2014 financial results at the close of the U.S. markets...


Jul 17, 2014, 12:38 ET InterMune Receives FDA Breakthough Therapy Designation For Pirfenidone, An Investigational Treatment For IPF

 InterMune, Inc. (Nasdaq: ITMN) today announced that pirfenidone has been granted Breakthrough Therapy Designation from the U.S. Food and Drug...


May 27, 2014, 07:00 ET InterMune Announces Resubmission Of NDA For Pirfenidone For The Treatment Of Patients With IPF

InterMune, Inc. (Nasdaq: ITMN) today announced that it has resubmitted its pirfenidone New Drug Application (NDA) to the U.S. Food and Drug...


May 20, 2014, 17:00 ET InterMune Announces Additional Pirfenidone Data in Idiopathic Pulmonary Fibrosis

 InterMune, Inc. (NASDAQ: ITMN) today announced that results of analyses of pooled data from the ASCEND trial and the two previous Phase 3...


May 18, 2014, 17:02 ET Phase 3 ASCEND Study of Pirfenidone in Idiopathic Pulmonary Fibrosis Presented at American Thoracic Society (ATS) and Published in New England Journal of Medicine

InterMune, Inc. (NASDAQ: ITMN) today reported that results from the Phase 3 ASCEND study evaluating pirfenidone in patients with idiopathic...


May 16, 2014, 08:00 ET InterMune Announces Expanded Access Program for Pirfenidone to Treat Idiopathic Pulmonary Fibrosis (IPF) in the United States

 InterMune, Inc. (NASDAQ: ITMN) today announced it will provide compassionate use of pirfenidone through a multi-center Expanded Access...


May 12, 2014, 08:00 ET InterMune Announces Upcoming Data Presentations at 2014 American Thoracic Society Meeting

 InterMune, Inc. (NASDAQ: ITMN) today announced that several investigational molecules and data from studies of pirfenidone will be presented...


May 01, 2014, 16:01 ET InterMune Reports First Quarter 2014 Financial Results, Clinical Development and Business Highlights

 InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the first quarter ended March 31, 2014.  The company also...


Apr 23, 2014, 08:00 ET InterMune To Release First Quarter Financial Results On May 1

 InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its first quarter 2014 financial results at the close of the U.S. markets...


Mar 13, 2014, 19:20 ET InterMune Announces Pricing of Public Offering of 7,500,000 Shares of Common Stock

InterMune, Inc. (Nasdaq: ITMN) today announced that it has agreed to sell 7,500,000 shares of its common stock at a price to the public of $32.75...


Mar 12, 2014, 16:02 ET InterMune Announces Proposed Public Offering of Common Stock

 InterMune, Inc. (NASDAQ: ITMN) today announced that it plans to offer, subject to market and other conditions, 7,500,000 shares of its common...


Feb 25, 2014, 07:00 ET InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF)

 InterMune, Inc. (NASDAQ: ITMN) today announced that top-line data from ASCEND, a Phase 3 trial evaluating pirfenidone in patients with...


Jan 09, 2014, 07:30 ET InterMune Reports Preliminary Fourth Quarter 2013 Esbriet® (pirfenidone) Revenue and Recent Business Highlights

 InterMune, Inc. (NASDAQ: ITMN) today announced unaudited revenue for the fourth quarter and year ended December 31, 2013.  The company...


Jan 06, 2014, 08:00 ET InterMune to Present at J. P. Morgan Healthcare Conference

 InterMune, Inc. (NASDAQ: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at...


Dec 10, 2013, 08:00 ET InterMune Announces Support of The Pulmonary Fibrosis Foundation Care Center Network and Patient Registry Initiative

InterMune (NASDAQ: ITMN) today announced its support of the Pulmonary Fibrosis Foundation, a leading patient advocacy organization dedicated...


Nov 05, 2013, 21:25 ET InterMune Announces Pricing of Public Offering of 6,500,000 Shares of Common Stock

InterMune, Inc. (Nasdaq: ITMN) today announced that it has agreed to sell 6,500,000 shares of its common stock at a price to the public of $13.00...


Nov 04, 2013, 16:00 ET InterMune Announces Proposed Public Offering of Common Stock

InterMune, Inc. (NASDAQ: ITMN) today announced that it plans to offer, subject to market and other conditions, 6,500,000 shares of its common stock...


Oct 30, 2013, 16:00 ET InterMune Reports Third Quarter 2013 Financial Results And Business Highlights

 InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the third quarter and nine months ended September 30, 2013, and...


Oct 23, 2013, 08:00 ET InterMune To Release Third Quarter Financial Results On October 30

InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its third quarter 2013 financial results at the close of the U.S. markets on...


Sep 24, 2013, 08:00 ET Andrew Powell Joins InterMune As Executive Vice President And General Counsel

InterMune, Inc. (NASDAQ: ITMN) today announced that Andrew Powell has joined InterMune as Executive Vice President, General Counsel and Corporate...


Sep 20, 2013, 00:01 ET Idiopathic pulmonary fibrosis (IPF) community emphasizes the power of united support for patients during IPF World Week 2013

This year's IPF World Week (September 21-29) sees healthcare professionals, patient advocacy groups, people living with idiopathic pulmonary...